Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2002-06-05
2008-11-11
Campell, Bruce (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388150, C530S388100, C424S139100, C424S142100, C424S130100
Reexamination Certificate
active
07449556
ABSTRACT:
The purpose of this project was to isolate recombinant antibodies for diagnosis of very virulent infectious bursal disease virus (vvIBDV) in fixed tissues. Phage-displayed recombinant antibodies, comprised of the single chain variable fragment (scFv), were investigated. A previously made recombinant antibody library generated against vvIBDV was selected and screened for recombinant antibodies that reacted against vvIBDV in ELISA. A new library was constructed fom chickens immunized with fixed vvIBDV and also screened for recombinant antibodies against vvIBDV. Also, a previously identified recombinant antibody, known to react well with vvIBDV, was used to replace either the Vh or VI gene with corresponding fragments from a new library. The Vh and VI antibody genes were initially amplified effectively by PCR. No new recombinant antibody clones were isolated from the libraries generated against vvIBDV. However, exchanging the Vh or VI genes from a known recombinant antibody with genes from a new library showed that the heavy chain was essential when binding to vvBDV. Light chains could be exchanged without loss of activity, but when heavy chains were exchanged, all activity was lost. The light chains were found to create new binding properties when combined with the essential heavy chain. The recombinant antibody clones were sequenced, analyszd and characterize.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5605827 (1997-02-01), Jackwood et al.
patent: 6528063 (2003-03-01), Stram et al.
patent: 32 18 121 (1983-11-01), None
patent: 0 036 676 (1981-09-01), None
patent: 0 052 322 (1982-05-01), None
patent: 0 058 481 (1982-08-01), None
patent: 0 073 657 (1983-03-01), None
patent: 0 088 046 (1983-09-01), None
patent: 0 102 324 (1984-03-01), None
patent: 0 133 988 (1985-03-01), None
patent: 0 142 641 (1985-05-01), None
patent: 0 143 949 (1985-12-01), None
patent: 60-7934 (1985-01-01), None
patent: WO 90/15140 (1990-12-01), None
patent: WO 91/16925 (1991-11-01), None
patent: WO 93/07282 (1993-04-01), None
patent: WO 01/62907 (2001-02-01), None
Eterradossi et al. Modified activity of a VP2-located neutralizing epitope on various vaccine, pathogenic and hypervirulent strains of infectious bursal disease virus. (1997) Archives in Virology, 142, pp. 255-270.
Clarkson et al. Making antibody fragments using phage displey libraries. (1991) Nature vol. 352, pp. 624-628.
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. PNAS, 1982, vol. 79, p. 1979-1983.
Panka et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies, PNAS, 1988, vol. 85, p. 3080-3084.
Sambrook et al.Molecular Cloning: A Laboratory Manual, 2nd Ed. vols. 1-3, (1989).
Maniatis et al. InMolecular Cloning: A Laboratory Manual., pp. 280-281 (1989).
Voller et al. (Ed.) Immunoassays for the 80's. University Park, pp. 205-288, 325-360, 457-479 (1981).
Hunter et al. “Preparation of iodine-131 labelled human growth hormone of high specific activity”.Nature, vol. 144, pp. 495 (1962).
David et al. “Protein iodination with solid state lactoperoxidase”.Biochemistry, vol. 13, No. 55, pp. 1014-1021 (1974).
Pain et al. “Preparation of protein a-peroxidase monocunjucate using a heterobifunctional reagent, and its use in enzyme immunoassays”.Journal of Immunological Methods, vol. 40, pp. 219-230 (1981).
Nygren. “Conjugation of horseradish peroxidase to fab fragments with different homobifunctional and heterobifunctional cross-linking reagents”.The Journal of Histochemistry and Cytocheimistry, vol. 30, No. 5, pp. 407-412 (1982).
Work (Ed.)Laboratory Techniques in Biochemistry and Molecular Biology, vol. 6, (1978).
Hood et al.Immunology, 2nd Ed. pp. 384 (1984).
Osol (Ed.) Remington's Pharmaceutical Sciences, 16th Ed.cpp. 1355, 1369, 1378 (1980).
Langer. “Controlled release of macromolecules”.Chemtech, vol. 12, pp. 98-105 (1982).
Langer et al. “Biocompatibility of polymeric delivery systems for macromolecules”.Journal of Biomedical Materials Research, vol. 15, pp. 267-277 (1981).
Sidman et al. “Controlled release of macromolecules and pharmaceuticals from synthetic polypeptides based on glutamic acid”.Biopolymers, vol. 22, pp. 547-556 (1983).
Eppstein et al. “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor”.Proc. Natl. Acad. Sci., USA, vol. 82, pp. 3688-3692 (Jun. 1985).
Hwang et al. “Hepatic uptake and degradation of unilamellar sphingomyelin/choloesterol liposomes: a kinetic study”.Proc. Natl. Acad. Sci., USA, vol. 77, No. 7, pp. 4080-4084 (Jul. 1980).
Glover (Ed.) DNA Cloning, vol. 1. pp. 101-133, 151-163 (1985).
McCafferty et al. (Eds.)Antibody Engineering. pp. 253-268 (1996).
Firth. “Occurrence of an infectious bursal syndrome within an Australian poultry flock”.Australian Veterinary Journal, vol. 50, pp. 128-130 (1974).
Brown et al. “VP2 sequences of recent European ‘very virulent’ isolates of infectious bursal disease virus are closely related to each other but are distinct from those of ‘classical’ strains”.Journal of General Virology, vol. 75, pp. 675-680 (1994).
Sapats et al. “Antigenic and sequence heterogeneity of infectious bursal disease virus strains isolated in Australia”.Arch Virol, vol. 145, pp. 773-785 (2000).
Ignjatovic et al. “Confirmation of the existence of two distinct genetic groups of infectious bursal disease virus in Australia”.Australian Veterinary Journal, vol. 80, No. 11, (Nov. 2002).
Bayliss et al. “A comparison of the sequences of segment A of four infectious bursal disease virus strains and identification of a variable region in VP2”.Journal of General Virology, vol. 71, pp. 1303-1312 (1990).
Heine et al. “Sequence analysis and expression of the host-protective immunogen VP2 of a variant strain of infectious bursal disease virus which can circumvent vaccination with standard type I strains”.Journal of General Virology, vol. 72, pp. 1835-1843 (1991).
Eterradossi et al. “Modified activity of a VP2-located neutralizing epitope on various vaccine, pathogenic and hypervirulent strains of infectious bursal disease virus”.Arch Virol, vol. 142, pp. 255-270 (1997).
Parede et al. “Characterization of infectious bursal disease virus isolates from Indonesia indicates the existence of very virulent strains with unique genetic changes”.Avian Pathology, vol. 32, No. 5, pp. 511-518 (2003).
Griffiths et al. “Human anti-self antibodies with high specificity from phage display libraries”.The EMBO Journal, vol. 12, No. 2, pp. 725-734 (1993).
Thompson et al. “The CLUSTAL—X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools”.Nucleic Acids Research, vol. 25, No. 24, pp. 4876-4882 (1997).
Fahey et al. “Virus-neutralizing and passively protective monoclonal antibodies to infectious bursal disease virus of chickens”.Avian Diseases, vol. 35, pp. 365-373 (1991).
Whitfill et al. “Determination of optimum formulation of a novel infectious bursal disease (IBDV) vaccine constructed by mixing bursal disease antibody with IBDV”.Avian Diseases, vol. 39, pp. 687-699 (1995).
Haddad et al. “Efficacy of a novel infectious bursal disease virus immune complex vaccine in broiler chickens”.Avian Diseases, vol. 41, pp. 822-889 (1997).
Jeurissen et al. “The working mechanism of an immune complex vaccine that protects chickens against infectious bursal disease”.Immunology, vol. 95, pp. 494-500 (1998).
Sapats et al. “Antigenic and sequence heterogeneity of infectious bursal disease virus strains isolated in Australia.”Archives of Virologoy(2000) vol. 14
Heine Hans G.
Ignjatovic Jagodina
Prowse Stephen
Sapats Sandra I.
Boesen Agnieszka
Campell Bruce
Commonwealth Scientific and Industrial Organisation
Merchant & Gould P.C.
LandOfFree
Recombinant antibodies against infectious bursal disease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant antibodies against infectious bursal disease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant antibodies against infectious bursal disease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4041277